Abstract TGF-b is a pro-fibrogenic and antiproliferative protein with multiple functions depending on the cellular context. In liver fibrosis, TGF-b was identified as very robust driver of hepatic stellate cell (HSC) activation and extracellular matrix production, and a plethora of approaches targeting the TGF-b signaling pathway were successfully used to tackle fibrogenesis in animal models of chronic liver diseases. The present review builds on knowledge of the last two decades about TGF-b function in myofibroblast generation and fibrogenesis, and presents the milestone discoveries from the recent 3-5 years. These include findings on downstream targets with fibrogenic function, pathways that facilitate TGF-b expression in HSC, and miRNAs regulated by or regulating the TGF-b pathway. Further, recent data on TGF-b signaling, its integration with other pathways, and TGF-b signaling regulators identified in the setting of fibrotic liver disease are provided. Additionally, we will discuss TGF-b and epithelial-to-mesenchymal transition in liver fibrosis, and what we have learned from other fibrotic diseases, besides liver. Finally, challenges and opportunities for TGF-b-directed therapies in HSC activation, liver fibrosis, and disease progression are discussed.
Introduction

TGF-b Signaling
TGF-b signaling regulates cellular fate including proliferation, plasticity, differentiation, and cell death [1] . Activation of the TGF-b receptor complex by TGF-b leads to phosphorylation of the intracellular signal mediators Smad2 and Smad3 (Smad2/3). Upon phosphorylation, these so-called receptor Smads associate with Smad4 and accumulate in the nuclei [2] . Smad3 and Smad2 can both bind to DNA through Smad-binding elements (SBE) [3 • ]. However, due to a rather low binding affinity, Smad proteins are in need of transcriptional cofactors to stabilize complex formation with DNA.
Inhibitory Smads (I-Smads), Smad6 and Smad7, function as negative regulators of TGF-b signaling via an autoinhibitory feedback loop. Additionally, upregulation of I-Smads can occur from cross-talking parallel signaling pathways. I-Smad regulation is mainly transcriptional and via post-translational protein degradation. Tight control of intracellular levels of I-Smads is necessary to maintain homeostasis. Up-or downregulated I-Smad levels may have a major impact on TGF-b signaling, thus eventually facilitating disease development [4] .
Besides the Smads, TGF-b is able to transmit signals via several alternative pathways to mediate cellular functions.
Such ''non-canonical'' pathways include, among others, MAP kinase, Rho-like GTPase, and phosphatidylinositol-3-kinase/AKT pathways. Non-Smad signaling proteins participate in three possible ways to TGF-b action, that is (1) targeting and modifying Smads (e.g., linker phosphorylation), (2) modulatory protein-protein interaction between Smads and downstream mediators of other signaling proteins (e.g., kinases or STATs), and (3) direct modulation of non-Smad signaling mediators via the TGFb receptors (e.g., TAK1). Thus, communication between TGF-b-mediated Smad and non-Smad signaling provides fine tuning of the signaling pathway, crosstalk with other signaling pathways and its outcome with regard to cellular fate [5, 6] .
Liver Fibrosis
Fibrosis is a highly conserved and coordinated protective response to tissue injury. Interaction of variant cell types, multiple pathways, and molecules determines whether fibrogenesis is self-limiting, providing a homeostatic wound healing response, or whether it is chronic and excessive [7] . Mechanisms of fibrogenesis comprise hepatic stellate cells (HSC) activation, recruitment, and multiplication of macrophages with inflammatory or fibrolytic phenotypes, discrete signals from inflammatory cell subsets and, 'ductular reaction,' the artificial bile duct formation based on bile duct epithelial cell proliferation, as a marker of severe injury and repair.
Hepatic Stellate Cells and Myofibroblasts
The principal producers of extracellular matrix (ECM) during liver fibrogenesis are myofibroblasts (MFB). Different origins of activated fibroblasts have been proposed, but HSC are considered to be the major source of fibrogenic cells in most chronic liver diseases (CLD) that concur with liver fibrosis, although portal fibroblasts could play a role in the fibrogenic process during cholestatic liver diseases.
TGF-b in Chronic Liver Disease-Short Summary of the Previous State of the Art
TGF-b is central in chronic liver disease, contributing to all stages of disease progression from initial liver injury through inflammation and fibrosis to cirrhosis and hepatocellular carcinoma. In normal liver, only sinusoidal endothelial cells and Kupffer cells (KC, macrophages) express relatively high levels of TGF-b mRNA. In response to liver damage, the three different TGF-b isoforms are induced in activated HSC [8] . Increased availability of TGF-b enhances hepatocyte damage and triggers HSC activation and extracellular matrix deposition, critical steps in the wound healing response of the damaged organ. Being a major pro-fibrogenic cytokine, targeting TGF-b and its signaling pathway in various animal models of CLD has provided promising results [9] .
TGF-b Effects on HSC Activation
Oxidative stress plays a relevant role in the sequence of events following TGF-b activation of HSC. Recent Indeed, regulation of ACAT activity in HSC could be a target for treatment of liver fibrosis.
The receptor for activated C-kinase 1 (RACK1), a scaffold protein involved in numerous cellular processes and signaling pathways, is a direct downstream target of TGF-b in activated HSC [18] . Interestingly, the TGF-b effect is mediated through NF-jB signaling. RACK1 then vice versa promotes activation of pro-fibrogenic pathways in a TGF-b and platelet-derived growth factor (PDGF)-mediated manner, contributing to differentiation, proliferation, and migration of HSC [18] . Further, RACK1 promotes assembly of eIF4F and phosphorylation of eIF4E in HSC, which enhances cap-dependent translation of pro-fibrogenic factors, such as collagen1a1 (Col1a1), Snail, or cyclin E1 [19] .
Although migration of HSC is essential for liver fibrogenesis, the intracellular and extracellular signals that regulate it are not well understood. There is now evidence that Rho guanosine triphosphatase (Rho GTPase) signaling mediates TGF-b-induced HSC cytoskeletal remodeling and migration [20] . Additionally, the axonal guidance molecule neuropilin-1 (NRP-1) is upregulated in activated HSC with a highly motile MFB phenotype [21 •• ]. NRP-1 co-localizes with the PDGF-b receptor and knockdown of NRP-1 attenuates chemotaxis induced by PDGF. Furthermore, NRP-1 overexpression increases cell motility and TGF-bdependent expression of profibrotic genes. These studies reveal a role for NRP-1 as a modulator of TGF-b and PDGF fibrogenic signaling and HSC migration.
Another relevant feature of activated HSC is proliferation. TGF-b, per se a proliferation inhibitor for epithelial cells, e.g., for hepatocytes in liver regeneration, in contrast provides growth stimulatory effects toward activated HSC in vitro. Now it is obvious that this effect is mimicked by 
Pathways Leading to TGF-b Expression in HSC
Many factors are implicated in production and activation of TGF-b in liver fibrogenesis. Here, we give an overview about those we consider the most relevant or that were just recently identified.
Signal transducer and activator of transcription (Stat3) is a transcription factor that regulates expression of many target genes, including TGF-b. In liver fibrogenesis, Stat3 has a dual role, protective in preventing liver fibrosis [25 •• ], or promoting liver fibrogenesis by upregulating TGF-b [26] . In a recent study, Stat3 and TGF-b levels were found increased in patients with advanced fibrosis as compared to patients with early disease stages. Similarly, in DEN-induced fibrosis in rats, high p-Stat3 levels correspond with high TGF-b expression and increased liver fibrosis grades [27] . More studies are necessary to establish how TGF-b and Stat3 signaling pathways integrate in CLD development and progression.
Hepatocyte growth factor (HGF) is known to regulate TGFb action. HGF suppresses hepatocyte apoptosis and stimulates hepatocyte proliferation during regeneration following liver injury. Further, it suppresses TGF-b gene expression in HSC, thus decreasing a-SMA production and collagen I, III synthesis. In rat HSCs, besides TGF-b, HGF also reduced the expression of Plasminogen Activator Inhibitor-1 (PAI-1) and Tissue Inhibitors of Matrix metalloproteinases-2 genes. Cocultures of hepatocytes and rat HSC (HSC-T6) that were treated with HGF showed an increase in overall plasmin levels and a decrease in fibrotic markers, even though TGF-b levels were not altered. These results suggest that HGF therapy might suppress TGF-b actions, thus reducing fibrogenesis and repopulating the damaged liver parenchyma with healthy hepatocytes instead of scar tissue [28 • ].
Another major contributor toward fibrogenesis is Human antigen R (HuR), a member of the Hu/Elav family. HuR has a role in HGF-induced hepatocyte proliferation, differentiation, and apoptosis and was found highly expressed in activated HSC. On the other hand, several miRNAs can modulate expression, synthesis, and function of TGF-b, either directly or indirectly. miR-424 downregulates Smurf2, a known negative regulator of the TGF-b pathway, and thus enhances TGF-b signaling [37] . Others like miR-454 and miR-146-a attenuate TGF-b signaling and inhibit HSC activation by targeting smad4 [38, 39 • ]. miR-30 upregulates Smad7 indirectly through targeting Krüppel-like factor 11 (KLF11), a TGF-b target gene that inhibits Smad7 transcription through recruiting the mSin3a histone deacetylase (HDAC) co-repressor complex to its promoter [40, 41] . In contrast, miR-17-5p targets smad7 directly, thereby enhancing TGF-b signaling and HSC activation. Inhibition of its action significantly attenuated TGF-b-mediated expression of Collagen 1a1 and a-SMA in HSC [42 • ]. Moreover, miR-200a targets both TGF-b2 and b-catenin to decrease protein expression, which leads to reduced a-SMA and inhibition of HSC proliferation [43] . Finally, miR-21 was found involved in an interesting autoregulatory feedback loop with AP-1 and programmed cell death protein 4 (PDCD4), which maintain its high expression in activated HSC during hepatic fibrosis development [44] . Interference with this loop using DIM (3,3 0 -Diindolylmethane), which is directed toward AP-1 activity, results in downregulated miR-21 expression, TGF-b signaling inhibition, and amelioration of liver fibrogenesis [45] .
TGF-b Signaling in HSC Activation and Liver Fibrogenesis
New signaling molecules and effectors (respective new functions of known ones) come continuously into the scene of TGF-b actions steadily increasing complexity of the pathway. Those include Smad2, Smad phosphoisoforms, TGF-b-Alk1-Smad1/5 signaling, and non-Smad proteins, e.g., membrane-anchored proteins and cationic channels.
Smad2
Smad2 and Smad3 have high similarity regarding their amino acid sequence and some of their biological functions [46] . Although some distinct roles have been reported, the relationship and the interaction between Smad2 and Smad3 is still poorly understood. Recently, it has been reported that Smad2 can protect against Smad3-mediated fibrogenesis by suppressing its phosphorylation and nuclear translocation [47 • ], which will motivate further studies to clarify in more detail the molecular mechanisms and the clinical application of such interaction.
Phospho-Smad Isoforms
Upon receptor stimulation, Smad proteins are activated by phosphorylation either at the carboxy group (pSmad2C and pSmad3C) or at the intermediate linker region (pSmad2L and pSmad3L) or at both (pSmad2C/L and pSmad3C/L). The carboxy terminal phosphorylation is mediated mainly by TGF-b, while linker phosphorylation is mediated by MAPKand/or JNK/CDK4-dependent mechanisms [48, 49] . Interestingly, these isoforms can partially explain the differential roles of TGF-b in HSC during acute and chronic hepatic injury. In acute liver damage, pSmad2C and pSmad3C are induced by TGF-b and inhibit c-myc gene expression in HSC, which results in growth inhibition and Smad7 expression, which downregulates TGF-b signaling in a negative feedback loop. In parallel, TGF-b facilitates HSC proliferation and collagen synthesis by CDK4-pSmad2L/C and pSmad3L/C, thus permitting tissue repair. In contrast, during chronic liver injury, linker-phosphorylated Smads (pSmad2L and pSmad3L) are produced by JNK-mediated fibrogenic signaling, e.g., via PDGF. pSmad3L translocates into the nucleus with Smad4 and induces c-myc expression and HSC proliferation. pSmad3/L is not able to elicit Smad7 expression, which enhances TGF-b actions, constitutively promoting ECM deposition leading to fibrosis and scarring [48, 49] . In addition, these phospho-Smad isoforms can partially explain why the cytostatic effect of TGF-b is lost during hepatocarcinogenesis. An interesting study by Yamaguchi et al., shows that during the course of Hepatitis C Virus (HCV) progression, R-Smad signaling shifts from tumor inhibiting (pSmad3C) to fibrogenic and carcinogenic pSmad2L/C and pSmad3L [50 • ]. In regard to loss of cytostatic TGF-b effects, we and others found that in some settings, Smad7 can interfere with the tumor suppressive action of TGF-b in early stages of hepatocellular carcinoma (HCC), thereby modulating tumor growth [51] [52] [53] .
ALK1-Smad1/5/8 Signaling
Whereas ALK5/pSmad2/3 in HSC activation and ECM production is well established [54] , participation of ALK1/ pSmad1/5/8 signaling on liver fibrogenesis is still controversial. TGF-b-dependent ALK1/Smad1/5/8 phosphorylation induces inhibitor of differentiation 1 (Id1) expression and potentiates HSC transdifferentiation into MFB [55 • ]. In contrast, partial ALK1 knock out increases ECM expression, proliferation, and migration of mouse embryonic fibroblasts, suggesting an antifibrogenic role [56] . In this context, it is noteworthy that BMP7, which is discussed as antifibrogenic, also signals along Smad1/5/8. Further and more thorough investigations are necessary to delineate the detailed role of the TGF-b/ALK1 axis and pSmad1/5/8 in liver fibrogenesis. signaling is used by TGF-b to induce HSC proliferation and AKT activation, whereas it does not participate in TGF-binduced collagen a1 production [57] . Another membranebound protein, Semaphorin 7A (SEMA7A), is increasingly expressed during HSC activation. In addition, its expression is induced by TGF-b Smad2/3-independent signaling and increases the expression of inflammatory markers. Interestingly, TGF-b itself can be induced by SEMA7A, presenting a positive feedback loop that perpetuates fibrogenesis [58] .
TGF-b Non-Smad Signaling
TGF-b Signaling Regulators in HSC Activation and Fibrogenesis
In our view, TGF-b signaling regulation offers the most exciting recent prospects regarding the TGF-b-related individual diversity of liver disease progression in patients progressing to highly severe and malignant stages. Modulating such regulators has a high potential to pave the way for personalized therapeutic approaches upon careful molecular/morphological investigation. TGF-b underlies multiple levels of regulation from ligand activation to target gene selection. Progress in research about TGF-b signaling regulators (TSR) in the last 3-4 years identified major impact of new TSR and revealed new mechanistic details for already known TSR (summarized in Fig. 1 ).
VASP, PDGFRa, BuB1, and CLIC4 [60] . Further, BUB1 (budding uninhibited by benzimidazoles-1) kinase, which is important for cell cycle regulation, modulates TGF-b signaling by promoting heterodimeric TbRI/RII complex formation. Knockdown of BuB1 inhibited both canonical (pSmad2/3) and non-canonical (AKT/MAPK) arms of TGF-b signaling [61] . By a completely different mechanism, Chloride Intracellular Channel 4 (CLIC4) is used by TGF-b to activate p38/MAPK, thus enhancing TGF-b activity in cancer stroma fibroblasts [62] . Previously, CLIC4 was shown to modulate TGF-b signaling through stabilizing pSmad2 and pSmad3 in the nucleus by preventing dephosphorylation [63 • ].
Smad7
Smad7 is a well-known negative modulator of TGF-b signaling [64] . Recently, new mechanisms for its regulation were shown, e.g., epigenetic repression of Smad7 expression in MFB of diseased liver, mediated by upregulation of DNA methyltransferase 1 enzyme (DNMT1), thus facilitating fibrogenic TGF-b effects [65] . Then miRNA-based mechanisms were discovered, as already described above (miR-17-5p; [42 • ] and miR-30 [40] ).
TLR-4
TLR-4 stimulation can sensitize HSC to TGF-b through downregulating BAMBI, a transmembrane TGF-b 
NR4A1
NR4A1 is an orphan nuclear receptor, which basically was identified as regulator of glucose and lipid metabolism as well as mediator of inflammatory responses [68] [69] [70] . Adenosine Monophosphate-Activated Protein Kinase (AMPK)
AMPK inhibits fibrogenic TGF-b activity in HSC through proteosomal degradation of p300, which is important for full fibrogenic activity of the Smad3/4 complex. Metformin, the well-known oral antidiabetic drug, is used to induce AMPK, representing an obvious possibility to treat diabetic patients complicated with liver fibrosis [73 • ].
Sharp1
Sharp1 is a basic helix-loop-helix (bHLH) transcriptional repressor that participates in various physiological . It has been recently described that TGF-b forms many interactions with other cytokines in liver fibrogenesis. One of the most relevant is the interaction with the Epidermal Growth Factor (EGF) pathway. Endogenous and exogenous Heparin-binding EGF (HB-EGF) inhibited HSC activation in primary cell culture, however enhanced HSC migration [79] , suggesting that HB-EGF expression or action is associated with suppression of fibrogenic pathways in HSC. Interestingly, HB-EGF may antagonize TGF-b-induced collagen expression in HSC via stabilization of the TGF-b-interacting factor (TGIF), a known Smad transcriptional co-repressor [80] .
Different examples of cooperative signaling between inflammatory cytokines and pro-fibrogenic TGF-b were recently proposed: IL-17A was found to enhance the expression of profibrotic genes in HSC, through JNK pathway-dependent upregulation of the TGF-b II receptor [81 • ]. Similarly, IL-13 induced CTGF expression in HSC by activating the TGF-b-independent activin receptor-like kinase/Smad signaling via the ERK-MAPK pathway [82 • ]. Together these results provide new insights into the molecular mechanism of pro-fibrogenic IL signaling in the liver. The activation of TGF-b or IL-13 signaling as a fibrogenic trigger depends on the cause of liver damage. TGF-b is driving HBV-related liver fibrogenesis, whereas IL-13 found in Schistosomiasis initiated liver disease and chronic HCV infection [83 • ].
Fibrogenic TGF-b Effects in Hepatocytes and Other Liver Cell Types
In addition to its role in transactivating HSC to MFB, TGFb also participates in the development of fibrosis through signaling in other liver cell types. A critical issue here is the balance between apoptosis and survival, which triggers hepatocyte fate and organ response toward regeneration, fibrosis, or transformation. TGF-b may induce apoptosis in hepatocytes [ . Similarly, E. Seki's group showed in a mouse NASH model based on feeding a choline-deficient amino acid (CDAA) diet that disease-related activation of Smad2/3, lipid accumulation, infiltration of inflammatory cells, death of hepatocytes, and fibrosis were significantly blunted in hepatocyte-specific TGF-b receptor type II-deficient (Tgfbr2DHEP) mice [91 •• ] . Wt mice fed the CDAA diet showed enhanced susceptibility to TGF-b-mediated hepatocyte death, which was blocked by silencing Smad2 or inhibiting ROS production, and was increased by inhibiting TAK1 (TGF-b-activated kinase-1) or nuclear factor kappa B signaling. These data indicate that TGF-b signaling in hepatocytes under metabolic stress mediates hepatocyte death and lipid accumulation, processes that require Smad signaling and ROS production, leading to the development of NASH. This is counteracted by parallel TGF-b/nonSmad/TAK1 survival signaling. Moreover, TAK1 deletion in hepatocytes results in spontaneous development of HCC, liver inflammation, and fibrosis. TGF-b signaling was increased in HCCs from Tak1DHep mice, whereas TAK1/ Tgfbr2DHep mice did not have this phenotype. Analyses of mechanistic details indicate that TGF-b promotes development of HCC in Tak1DHep mice through its effects on hepatocyte apoptosis, liver fibrogenesis, and compensatory proliferation during early steps of tumorigenesis, and by inducing the expression of anti-apoptotic, pro-oncogenic, and angiogenic factors during tumor progression [92 •• ] .
In a very simplified view, the liver initially responds to injury by inducing liver regeneration. If this is disturbed, e.g., in various liver diseases where the death rate of mature hepatocytes is chronically increased, the default mode will be liver fibrosis. Different evidences suggest that apoptosis and consequent phagocytosis of hepatocytes induce HSC activation and initiation of fibrogenesis [93] . Apoptotic cells are engulfed by liver phagocytes (the KC), by efferocytosis, or by HSC. Phagocytosis of apoptotic bodies activates NADPH oxidase 2 (NOX2), superoxide production, collagen a1 (I) expression, and production of TGF-b in HSC, whereas in KC, it stimulates death ligand expression [94 • 
Recently, the concept of damage-associated molecular patterns (DAMPs) as key inducers of inflammation following hepatocyte death was discussed. Schwabe and coworkers described that epithelial high-mobility group box 1 (HMGB1) is required for initiation of inflammation following injury, triggering recruitment of neutrophils through its receptor RAGE toward necrosis. HMGB1 thus represents as a bona fide and targetable DAMP that triggers a selective neutrophil-mediated injury amplification loop in the setting of tissue necrosis [95 • ]. Similarly, Jung et al. have shown that dying mature hepatocytes produce Hedgehog ligands, which provoke the compensatory proliferation of progenitors and MFB generation [96 • ]. These results may explain why diseases that chronically increase hepatocyte death promote cirrhosis. How hepatocyte TGFb signaling is directly or indirectly participating in hepatocyte DAMP signals has not been investigated yet.
Additionally to HSC and hepatocytes, other cell types are likely to contribute to liver fibrosis. Indeed, recent results indicate that neovessel formation (angiogenesis) accelerates liver fibrogenesis at least in part via provision of latent TGF-b that is later activated [97] . It is well known that hepatic progenitor cells (HPCs), which are activated in chronic liver injury, participate in progression of liver fibrosis, although their precise role is not fully understood. Recent evidence indicates that HPCs could contribute through TGF-b MAPK-dependent, Smad-independent production of CTGF [14 • ].
TGF-b and Epithelial Mesenchymal Transition in Liver Fibrogenesis
Over the past two decades, HSC have been considered as major source of MFB in the liver. However, many groups reported that epithelial hepatocytes exposed to TGF-b showed downregulation of epithelial markers, such as E-cadherin and induced expression of mesenchymal markers, such as vimentin and collagen a-1 [98, 99] . It was proposed that epithelial hepatocytes could change their phenotype and become MFB-like through epithelial-tomesenchymal transition (EMT). However, it has been challenging to recapitulate these findings in vivo. To overcome the difficulties in detecting the, often transient, EMT status and to track the source of MFB, novel techniques have been developed, such as lineage tracing. The first attempt in vivo to prove that hepatocytes could contribute to liver fibrogenesis using lineage tracing showed that up to 45 % of MFB were derived from hepatocytes via EMT [100] . Later, D. Brenner's group could show that this finding was based on the wrong assumption that FSP1/S100A4 in liver would be a marker of MFB [101 •• ] . The authors could convince us that FSP1 in liver is produced in macrophages. In line with these data, Taura et al. observed in CCl4-induced liver fibrosis upon lineage tracing not any functional collagen expressing MFB derived from hepatocytes [102 •• ] . Until now, many studies have been reported that are either for or against EMT contributing to liver fibrogenesis [98] . The discrepancies between different groups and the fact that conflicting results were generated using similar mouse models and lineage tracing (a subject matter that is also present for the determination of liver cell populations that contribute to liver regeneration) ask for further in vivo studies and novel techniques in order to finally confirm or discard involvement of EMT in liver fibrogenesis.
The relevance of TGF-b-induced EMT in liver fibrosis has also been evaluated by studies using bone morphogenetic protein-7 (BMP-7). BMP-7 is a member of the TGF-b superfamily and was reported to have an opposing role to TGF-b, and even can induce mesenchymal-to-epithelial transition (MET). Treatment of primary rat liver epithelial cells with TGF-b increases phosphorylation of Smad2/3, and expression of FSP-1 and a-SMA, whereas stimulation with BMP-7 upregulates E-cadherin and decreases pSmad2/3 and TGF-b levels. Moreover, in a rat CCl4 liver fibrosis model, treatment with TGF-b induced more advanced liver fibrosis together with enhanced expression of a-SMA and decreased expression of E-cadherin. This was rescued upon treatment with a combination of TGF-b and BMP-7 in a 1/10 ratio [103] . Previously, the same group showed that treatment with Snail induces EMT and treatment with BMP-7 could reverse the effect of Snail1 and induce MET in liver epithelial cell culture and in CCl4-induced rat liver fibrosis [104] . Also other studies demonstrated that BMP-7 is preventive in early stages of hepatic fibrosis, e.g., by inhibiting the expression of TGF-b in cultured HSC [105 • ] or by decreasing activation of HSC and downregulating TGF-b, EGFR, and a-SMA expression in CCl4-induced liver fibrosis in rat [106] . These results together suggest BMP-7 as antagonist of TGF-b and liver fibrogenesis.
TGF-b in Non-liver Fibrotic Diseases
The fibrogenic role of TGF-b is conserved in various organs. This is due to a large consistency in the wound healing response of damaged tissue. Therefore, much information from fibrosis related to other organs, e.g., pulmonary fibrosis, kidney fibrosis, and pancreatic fibrosis, translates also into liver disease. For example, Smad3 signaling can activate bone marrow-derived fibroblasts and mediates renal fibrosis [107] . Moreover, TGF-b and PDGF promote transdifferentiation of corneal stromal fibroblasts into MFB [108] . As a consequence, an efficient antifibrogenic approach targeting TGF-b signaling may probably be similarly efficient in any fibrotic disease. For example, pharmacological inhibition of ERK5 inhibited lung fibrosis and improved survival via modulation of Smad3 acetylation without affecting Smad3 phosphorylation [109 • ]. Modulation of TGF-b signaling using a histone deacetylase 1 blocker or an AMP-activated kinase agonist inhibits renal fibrogenesis and MFB activation [110, 111] . Interesting new findings show that Smad2 can produce opposite outcomes to Smad3, demonstrating antifibrotic activity in peritoneal fibrosis [112 • ]. Further, chronic dermal exposure to lipopolysaccharide (LPS) increases inflammatory chemokines and upregulates TGF-b signature genes [113] . When interpreting the role of signaling pathways, we must take into consideration that most are highly context and disease dynamics dependent. As an example, Notch signaling can play opposing roles in different aetiologies of fibrosis. Notch inhibition with DAPT enhances TGF-b-induced cardiac fibroblast activation [114] . In addition, silencing of Jagged-1, a Notch ligand, enhanced TGF-b-induced MFB transdifferentiation, as shown by increased a-SMA expression, and counteracted the inhibitory effect of Relaxin [114] . On the other hand, Notch signaling was activated in CCl4-induced liver fibrosis and its inhibition decreased collagen production and protected against liver fibrosis, an effect that was discussed as related to its ability to interfere with HSC plasticity in the fibrotic liver [115] . The conclusion of this chapter should be that we take into account findings in other fibrotic diseases, when trying to understand liver fibrogenesis.
Targeting TGF-b Signaling in HSC Activation and Liver Fibrosis
Due to the key role that TGF-b plays in activation of HSC and transdifferentiation into MFB, various approaches were experimentally applied to inhibit this signaling pathway, in the hope of developing an effective antifibrotic therapy [9] . Translation into clinical applications to tackle fibrogenesis, however, is difficult and has not been achieved yet. TGF-b is a pleotropic polypeptide that participates in various physiological and pathological conditions of the liver, including not only fibrogenesis, but also angiogenesis, EMT, cell proliferation, carcinogenesis, immune modulation, differentiation [116] , and liver regeneration [117] . Thus, simple inhibition of this important signaling pathway may be associated with serious adverse effects, like progression of cancer, which should be highly considered, especially with the knowledge that late-stage fibrotic and cirrhotic patients are at high risk of developing liver cancer. 
Herbal Medicine
Various herbal products have been investigated for its activity against liver fibrogenesis, and its ability to inhibit TGF-b signaling and HSC activation. For example, Mistletoe, the traditional herbal medicine in Asia, APE (Astragalus and Paeoniae Radix Rubra extract) and others can be protective against liver fibrogenesis through inhibiting Smad2 signaling and increasing Smad7 expression [120] [121] [122] . Expectedly, Silymarin, the well-known hepatoprotectant is effective toward CCl4-mediated liver fibrogenesis through its antioxidant activity and its ability to interfere with TGF-b expression [123] . cross-linking a TGF-b-derived polypeptide to a carrier protein to make it antigenic and induce high titer of neutralizing autoantibodies upon injection into animals. The approach was efficient against CCl4-induced liver fibrosis and significantly inhibited TGF-b signaling in HSC [125] . Fan et al. evaluated the protective rather than the therapeutic effect of the TGF-b vaccine. Testing the efficacy of such kind of vaccinations in already established fibrosis model and monitoring the potential side effects will be interesting.
Targeting TGF-b in HSC
Specific inhibition of TGF-b in activated HSC was achieved by coupling an ALK5 inhibitor to M6PHSA (human serum albumin modified with mannose 6 phosphate) as carrier. This leads to increased uptake of the compound inhibitor into HSC through the M6P/IGFII receptor that is mainly expressed on the surface of HSC and resulted in a stronger antifibrotic response as compared to delivery of the uncoupled inhibitor [126] . A pharmacological inhibitor, GKT137831, directed toward fibrogenic TGF-b mediator NOX4/NOX1 decreased expression of fibrogenic markers and hepatocyte apoptosis in BDL and CCl4 fibrosis models, thus representing a promising therapeutic agent for future research [11, 127] .
Conclusion and Outline
We have to ask ourselves the question why the promising results from animal models with chronic fibrotic diseases [128] . Therefore, a TGF-btargeted therapy for CLD needs careful estimation of time point and cell type of intervention. Next, interference with selected TGF-b downstream signaling branches/TGF-binduced cellular responses needs to be defined, e.g., blunting MFB formation in a setting of scarring could be envisioned to avoid undesired side effects that are associated with a complete disruption of TGF-b signaling. Further investigation is needed to delineate the complex outcome of TGF-b signaling in liver fibrogenesis, and to get more detailed knowledge about TGF-b signaling regulators to develop more specific and more effective TGF-bdirected therapies for translation into patients. 
